- How decentralized and hybrid solutions can be used to increase patient access to clinical trials
- In-home visits have benefits for participants, sites and sponsors
- How to ensure uptake and adoption to drive global results
- What’s next for the hybrid trial model
Archives: Agenda
KEYNOTE PANEL DISCUSSION: Navigating the current geo-political landscape as a small biotech
- Overviewing the current political landscape and understanding what the impact is on small biotech’s
- Adapting to change by effectively navigating a small biotech though uncertainty
- Understanding and leveraging new start-up opportunities by reviewing investment and marketing trends
PRIZE DRAW
Visit our exhibitors’ booths throughout the day and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple devices or Amazon giftcards. The Prize Draw will take place in the Exhibition Hall. Make sure you don’t miss out!
Designed to deliver: Unlocking the value of bespoke outsourcing models
- Move from siloed to integrated with a collaborative framework and culture
- Build an agile operating model for immediate and long-term success
- Unlock the value of strategic FSP: key examples of success
Tempus Ecosystem combines for smarter insight to precision medicine oncology trials
- Utilize multi-omics data from next-generation sequencing to build a smarter, data-driven trial design.
- Accelerate patient matching and enrollment through our extensive clinical trial site network.
- Combine these capabilities in an integrated ecosystem to build a better, more efficient clinical trial.
Afternoon refreshments and networking
Leverage the power of AI to optimize study site and CRA performance
- Growing trial complexity increases site questions and strains CRA resources
- RASPberry AI™ provides instant, accurate access to study-specific information
- Rapid answers improve site performance and CRA productivity
- Sponsors gain actionable insights into trial execution
Strategies for success when every patient counts: enhancing retention and protocol compliance in ultra-rare and genetic disorders
- In rare populations, every patient carries significant weight, making retention more critical than in most other therapeutic areas.
- Because patient numbers are extremely limited, attrition cannot be absorbed—losing even a single participant can jeopardize the entire study.
- Rare disease trials often focus heavily on recruitment, but retention is equally essential and frequently overlooked.
- Collaboration with the Community is key
- Case studies